Semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, has become one of the most important medicines of the decade, transforming treatment for type 2 diabetes and obesity. It has also been one of the most expensive. In 2026, that is beginning to change in much of the world, as key patents expire in large markets including India, China, Brazil and Canada.
India moves first
Semaglutide's core patent expired in India on March 20, 2026 [1][2]. Within about a day, a wave of Indian drugmakers launched generic versions. Natco Pharma was reported to be among the first, with prices starting at 1,290 rupees a month [3]. Sun Pharmaceutical Industries, India's largest drugmaker, launched two brands, Noveltreat for weight management and Sematrinity for diabetes, and companies including Dr. Reddy's Laboratories, Zydus Lifesciences, Glenmark, Torrent, Alkem and others followed [1][3][4]. According to ThePrint, generic launch prices ranged from about 1,300 to 4,200 rupees a month, compared with roughly 8,800 rupees for starting doses of Ozempic and 10,850 rupees for Wegovy [1]. Indian outlets reported price cuts of roughly 70% to 90% compared with the brand-name products [4][5]. India's market is significant on its own, but its role as a global supplier may matter even more. India produces a large share of the world's generic medicines and supplies more than half of Africa's generics, according to Agence France-Presse [2]. Dr. Reddy's has said it plans to produce 12 million pens in its first year and has announced plans to export to Canada, Brazil and Turkey [5].
A global patent cliff
India is not alone. Patents protecting semaglutide expire in 2026 in several large countries, including China, Brazil, Canada, South Africa and Turkey [2][6]. A study posted in March 2026 by a team of researchers led by Jacob Levi found that the 10 countries with 2026 patent expiries represent 44% of the world's population and 48% of the global obesity burden [6]. The same study estimated, based on shipment data for the drug's active ingredient, that generic injectable semaglutide could be produced for $28 to $140 per person per year [6]. That is a tiny fraction of what patients pay in many wealthy countries. The authors concluded that patent expiry "could substantially expand access to semaglutide at dramatically lower prices, particularly in high-burden settings" [6]. Their analysis has not yet been peer-reviewed. Before the patent expired in India, only about 200,000 patients there were taking GLP-1 drugs, the class of medicines that includes semaglutide, despite tens of millions of people with diabetes or obesity [7]. Prices at the low end have been striking. One trade publication reported that Alkem Laboratories was offering semaglutide in pre-filled pens starting at about $19 a month [4]. Public health experts say lower prices could make these drugs realistic options in national health programs in middle-income countries for the first time.
Beyond India
Canada, where semaglutide's patent protection also ends in 2026, is one of the first wealthy countries to open to generic competition, and Indian manufacturers have targeted it as an early export market [6]. Dr. Reddy's said it aimed to launch its version there by May 2026 [2]. Brazil, with one of the largest obesity burdens in the Americas, and China, with the world's largest number of people living with diabetes, are also expected to see generic competition this year [6]. The scale of the opportunity is large. The medRxiv study estimated that by the end of 2026, generic semaglutide could be legally available in about 160 countries that together account for 69% of the global burden of type 2 diabetes and 84% of the burden of clinical obesity [6]. Market analysts in India have estimated that the patent expiry could create more than 5,000 crore rupees, roughly $600 million, in new revenue for generic makers over 12 to 15 months across India, Brazil and Canada [1].
Why Americans won't see generics soon
In the United States, semaglutide remains under patent protection, with key patents expected to run into the early 2030s [7][8]. Novo Nordisk also holds additional patents in many countries covering formulations and delivery devices, so the expiration of the core patent does not automatically open every market [8]. That does not mean U.S. prices are standing still. Ozempic and Wegovy were among the drugs selected in the second round of Medicare drug price negotiations, and their negotiated Medicare prices take effect in 2027 [9]. Direct-to-consumer cash prices have also fallen as competition from Eli Lilly's tirzepatide and pressure from the federal government have grown. Still, the gap between what an Indian patient pays for a month of generic semaglutide, often under $50, and what many Americans pay remains enormous.
Quality and safety questions
The rapid flood of new products has raised quality questions. Semaglutide is a peptide, a molecule more complex to manufacture than a typical pill, and it is delivered by injection pen. Regulators in importing countries will need to verify that generic versions meet the same standards as the original. Manufacturers are aware of the concern; one Indian company launching in several countries told ThePrint it was committed to a "One Product, One Quality" approach across all markets [1]. Medical experts also note that semaglutide works best as part of supervised care, and that cheaper access could increase use without medical oversight.
Why it matters
The semaglutide patent cliff is shaping up to be one of the most important access stories in global health. In the past, generic competition from Indian manufacturers helped bring the cost of HIV treatment in Africa down from thousands of dollars per patient per year to a small fraction of that, making large-scale treatment programs possible. Some researchers see a similar opportunity with GLP-1 drugs for obesity and diabetes, conditions that are growing rapidly in low- and middle-income countries. Whether that potential is realized will depend on manufacturing quality, regulatory approvals and whether health systems can afford to offer the drugs widely, even at generic prices.
Sources
- 1. "Rs 325–4,200/month: Dr Reddy's, Sun Pharma, Glenmark kick off generic semaglutide price war," ThePrint, March 2026. https://theprint.in/india/rs-325-4200-month-dr-reddys-sun-pharma-glenmark-kick-of f-generic-semaglutide-price-war/2885525/
- 2. "India set to roll out cheap weight-loss jabs as demand rises amid obesity surge," AFP via Malay Mail, March 20, 2026. https://www.malaymail.com/news/world/2026/03/20/india-set-to-roll-out-cheap-weight-los s-jabs-as-demand-rises-amid-obesity-surge/213345
- 3. "Pharma News, 15 Mar 2026 to 21 Mar 2026" (generic semaglutide launches in India), PharSight/GreyB. https://pharsight.greyb.com/latest-drug-news/15-Mar-2026-to-21-Mar-2026
- 4. "India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply," DayTraders, March 23, 2026. https://daytraders.com/news/2026/03/23/india-generic-wave-hits-ozempic-wegovy-prices-drop
- 5. "Ozempic Patent Expiry: Have the Scales Finally Tipped?" Abel + Imray, April 17, 2026. https://www.abelimray.com/resources/newsletters/ozempic-patent-expiry-have-the-scales-finally-tipped
- 6. Jacob Levi, Samuel Cross, Nydile Ramesh, Francois Venter and Andrew Hill, "How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access Ahead of Patent Expiry," medRxiv preprint, March 2026. https://www.medrxiv.org/content/10.64898/2026.03.04.26347508v1.full-text
- 7. "India's Ozempic Race Has Begun," Sahi, 2026. https://www.sahi.com/blogs/semaglutide-patent-expiry-india-pharma-stocks-the-impact
- 8. "Cheap weight-loss jabs: India set to reshape global obesity fight," AFP via Gulf News, March 2026. https:// gulfnews.com/world/asia/india/cheap-weight-loss-jabs-india-set-to-reshape-global-obesity-fight-1.50048083 7
- 9. "CMS moves forward with 3rd round of Medicare drug negotiations," Becker's Hospital Review, March 2026. https://www.beckershospitalreview.com/pharmacy/15-drugs-selected-for-medicare-negotiation-program/ Information in this article is current as of October 9, 2026. Bracketed numbers refer to the sources listed above.